Catalyst Wire Dossier Catalyst Wire Dossier

IB1001

Recombinant Factor IX · Cangene Corporation
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for IB1001, covering 2016-08-23 to 2019-04-11. Get the full timeline:

Most recent: Clinical Trial Update: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B [Phase 3]

See pricing